ABSK 041
Alternative Names: ABSK-041Latest Information Update: 28 Nov 2023
At a glance
- Originator Abbisko Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for preclinical development in Cancer in China (PO)
- 18 Nov 2019 ABSK 041 is available for licensing as of 18 Nov 2019. http://www.abbisko.com/page105?_l=en
- 26 Oct 2019 Pharmacodynamics data from preclinical studies in Cancer presented at the 31st EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR)